Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-28

FDA Approved: MIRABEGRON — Original Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves Lupin's MIRABEGRON for the treatment of overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mirabegron (mirabegron)

Snippet

ORIG AP for MIRABEGRON (MIRABEGRON)